Molecular Neurodegeneration

(The TQCC of Molecular Neurodegeneration is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease479
Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease217
The role of TDP-43 mislocalization in amyotrophic lateral sclerosis200
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies131
Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease123
Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration119
Neuropathology and molecular diagnosis of Synucleinopathies118
Tauopathies: new perspectives and challenges115
APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease113
Solving neurodegeneration: common mechanisms and strategies for new treatments110
TDP-43 Pathology in Alzheimer’s Disease110
Proteomic landscape of Alzheimer’s Disease: novel insights into pathogenesis and biomarker discovery109
Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics106
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis105
Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease104
“Don’t Phos Over Tau”: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer’s disease and other tauopathies103
Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease102
Plaque associated microglia hyper-secrete extracellular vesicles and accelerate tau propagation in a humanized APP mouse model102
Cellular and pathological heterogeneity of primary tauopathies101
Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry100
New approaches to symptomatic treatments for Alzheimer’s disease96
METTL3-dependent RNA m6A dysregulation contributes to neurodegeneration in Alzheimer’s disease through aberrant cell cycle events95
Brain mechanisms underlying neuropsychiatric symptoms in Alzheimer’s disease: a systematic review of symptom-general and –specific lesion patterns94
Post-infection cognitive impairments in a cohort of elderly patients with COVID-1990
Extracellular protein components of amyloid plaques and their roles in Alzheimer’s disease pathology84
Glycosphingolipids and neuroinflammation in Parkinson’s disease80
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases80
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia79
Oligodendrocyte death and myelin loss in the cuprizone model: an updated overview of the intrinsic and extrinsic causes of cuprizone demyelination79
Plaque-associated human microglia accumulate lipid droplets in a chimeric model of Alzheimer’s disease76
P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice73
Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers70
The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored68
Protective genes and pathways in Alzheimer’s disease: moving towards precision interventions66
Microbial involvement in Alzheimer disease development and progression62
Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients59
Genome-wide histone acetylation analysis reveals altered transcriptional regulation in the Parkinson’s disease brain59
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives59
Impaired NHEJ repair in amyotrophic lateral sclerosis is associated with TDP-43 mutations57
Adult-onset CNS myelin sulfatide deficiency is sufficient to cause Alzheimer’s disease-like neuroinflammation and cognitive impairment57
The role of inflammasomes in vascular cognitive impairment54
Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer’s disease neuropathology51
Characterization of mitochondrial DNA quantity and quality in the human aged and Alzheimer’s disease brain51
The CD33 short isoform is a gain-of-function variant that enhances Aβ1–42 phagocytosis in microglia50
The Alzheimer’s disease-associated protective Plcγ2-P522R variant promotes immune functions50
Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis48
CNS axonal degeneration and transport deficits at the optic nerve head precede structural and functional loss of retinal ganglion cells in a mouse model of glaucoma47
Identification of sixteen novel candidate genes for late onset Parkinson’s disease47
Microglial TYROBP/DAP12 in Alzheimer’s disease: Transduction of physiological and pathological signals across TREM247
The informed road map to prevention of Alzheimer Disease: A call to arms46
A novel systems biology approach to evaluate mouse models of late-onset Alzheimer’s disease45
Alzheimer’s disease – the journey of a healthy brain into organ failure45
Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE145
Guidelines for bioinformatics of single-cell sequencing data analysis in Alzheimer’s disease: review, recommendation, implementation and application44
The landscape of human tissue and cell type specific expression and co-regulation of senescence genes44
Cholesterol alters mitophagy by impairing optineurin recruitment and lysosomal clearance in Alzheimer’s disease43
Trem2 deficiency differentially affects phenotype and transcriptome of human APOE3 and APOE4 mice43
TREM2 in the pathogenesis of AD: a lipid metabolism regulator and potential metabolic therapeutic target43
Deciphering cellular transcriptional alterations in Alzheimer’s disease brains42
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain41
CX3CR1 deficiency aggravates amyloid driven neuronal pathology and cognitive decline in Alzheimer’s disease41
FRET-based Tau seeding assay does not represent prion-like templated assembly of Tau filaments41
Trem2 deletion enhances tau dispersion and pathology through microglia exosomes41
APOΕ4 lowers energy expenditure in females and impairs glucose oxidation by increasing flux through aerobic glycolysis39
Modeling the β-secretase cleavage site and humanizing amyloid-beta precursor protein in rat and mouse to study Alzheimer’s disease38
TREM2 dependent and independent functions of microglia in Alzheimer’s disease38
Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis38
Mitochondrial complex I abnormalities is associated with tau and clinical symptoms in mild Alzheimer’s disease37
Sleep and circadian rhythms in Parkinson’s disease and preclinical models36
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration35
Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models35
BIN1 is a key regulator of proinflammatory and neurodegeneration-related activation in microglia35
Adiponectin-mimetic novel nonapeptide rescues aberrant neuronal metabolic-associated memory deficits in Alzheimer’s disease35
Human iPSC-derived astrocytes transplanted into the mouse brain undergo morphological changes in response to amyloid-β plaques35
Plasma phospho-tau in Alzheimer’s disease: towards diagnostic and therapeutic trial applications34
Altered network properties in C9ORF72 repeat expansion cortical neurons are due to synaptic dysfunction34
Pathophysiology and probable etiology of cerebral small vessel disease in vascular dementia and Alzheimer’s disease34
LRP1 is a neuronal receptor for α-synuclein uptake and spread33
Basal lamina changes in neurodegenerative disorders33
Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories32
Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia32
Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers32
Preclinical modeling of chronic inhibition of the Parkinson’s disease associated kinase LRRK2 reveals altered function of the endolysosomal system in vivo31
Tauopathy-associated tau modifications selectively impact neurodegeneration and mitophagy in a novel C. elegans single-copy transgenic model31
BIN1 protein isoforms are differentially expressed in astrocytes, neurons, and microglia: neuronal and astrocyte BIN1 are implicated in tau pathology31
Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer’s disease brains31
The role of inflammation in neurodegeneration: novel insights into the role of the immune system in C9orf72 HRE-mediated ALS/FTD30
Impaired antioxidant KEAP1-NRF2 system in amyotrophic lateral sclerosis: NRF2 activation as a potential therapeutic strategy30
Cellular stress signaling and the unfolded protein response in retinal degeneration: mechanisms and therapeutic implications30
Tau interactome and RNA binding proteins in neurodegenerative diseases30